Mutations in the lipid transporter ABCA7 are known to elevate the risk of Alzheimer’s disease, but how they do so has been murky. Now, scientists led by Li-Huei Tsai at MIT in Cambridge, Massachusetts ...
Antisense oligonucleotides have emerged as a promising approach for treating neurodegenerative disease. They can dial down toxic proteins or help restore functional ones, and have been approved for ...
The infamous paired helical filaments (PHFs) of tau that sprawl across the brain in Alzheimer’s disease are the end products of a multiyear process. What drives tau to form these specific filaments in ...
The network provides high-quality brain tissue to scientists and clinicians and supports major initiatives on research into neurological disorders, including the aims of the Ministerial Action Group ...
This interactive resource organizes decades of data on biomarkers for Alzheimer's disease. Biomarker measurements from the cerebrospinal fluid and blood are curated from the primary literature and ...
This active vaccine was designed to overcome the weak immune system of aged populations while avoiding auto-immune T cell responses. The Lu AF20513 epitope intersperses three repeats of the first 12 ...
It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...
After two years, half of AD patients taking gantenerumab become amyloid-negative. One-third develop ARIA-E, usually without symptoms. Lilly’s N3pG, directed against pyroglutamate Aβ, clears plaques in ...
Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...
Results of the eagerly awaited Phase 3 clinical trial of LMTM, a derivative of the dye methylene blue, generated consternation at the Alzheimer’s Association International Conference 2016, held July ...
The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback